Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up – Still a Buy?

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $48.24, but opened at $51.6950. Zealand Pharma A/S shares last traded at $51.6950, with a volume of 102 shares.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on ZLDPF shares. Wells Fargo & Company restated an “overweight” rating on shares of Zealand Pharma A/S in a report on Thursday, August 13th. Jefferies Financial Group lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Wolfe Research downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. Zacks Research cut Zealand Pharma A/S from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 13th. Finally, Berenberg Bank downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, June 17th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

Zealand Pharma A/S Price Performance

The company has a quick ratio of 37.17, a current ratio of 37.17 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $3.70 billion, a price-to-earnings ratio of 8.57 and a beta of 0.88. The stock’s 50 day moving average price is $46.45 and its two-hundred day moving average price is $48.59.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.